(Alliance News) - 4D Pharma PLC on Monday said it will undertake a study to evaluate the clinical efficacy of MRx0518 in combination with radiotherapy for the treatment of pancreatic cancer.
The trial will be undertaken in 15 patients with pancreatic cancer. The study will be conducted at the University of Texas MD Anderson Cancer Center as part of a strategic collaboration to evaluate 4D pharma's oncology product pipeline across a range of cancer settings.
"In addition to the primary endpoint of safety and tolerability, the study will evaluate the preliminary clinical efficacy of the combination including assessment of major pathologic response, Progression Free Survival and Overall Survival. Additional secondary and exploratory endpoints will assess changes in tumour infiltrating lymphocytes and the gut microbiome," the drug development company said.
Alex Stevenson, 4D's chief scientific officer, said: "Encouraged by promising early signals in our other clinical studies, we believe MRx0518 has the potential to offer new treatment options and dramatically improve outcomes for patients with pancreatic cancer."
4D Pharma shares in London were up marginally at 97.52 pence each in London.
By Tapan Panchal; tapanpanchal@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
